Page results
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
If you need an assessment by a midwife or doctor that is outside of your routine antenatal appointments you will be invited to attend the Maternal and Fetal Assessment Unit (MFAU).
-
Participants reacted quicker and made fewer errors during menstruation, despite believing their performance would be worse, according to new research from UCL and the Institute of Sport, Exercise & Health (ISEH).
-
Medtronic are running a series of patient webinars for anyone with Type 1 Diabetes using the MiniMed™ 780G pump or system.
-
New precision therapy for bile duct cancer extends patients’ lives
-
An immunotherapy drug given before surgery instead of chemotherapy meant that significantly more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
-
The Sickle Cell Society (SCS) and the UK Thalassaemia Society (UKTS) have worked in partnership with the NHS sickle cell and thalassaemia (SCT) screening programme to engage with communities less likely to access health information through usual NHS channels. The societies provide feedback from people that share the same population background or have experience of the condition and to feed into the programme updates and improvements.
-
Education and training videos for Red Cell Network patients
-
Information about endovascular treatments of AVMs undertaken in the NHNN angiography suite.
-
Information about coil embolisations and how endovascular treatment is used to treat cerebral aneurysms.
File results
-
FOI/2024/0148 - Cleaning audit system at Trust
-
FOI/2024/0149 - National Hospital for Neurology and Neurosurgery (NHNN) admissions 2018-2023
-
FOI/2024/0155 - Immunotherapy treatments for lung cancer
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments
-
FOI/2024/0166 - Recruitment systems/CRM platform
-
FOI/2024/0171 - Dermatology consultants
-
FOI/2024/0172 - Patients excluded from care at the Trust 2010-2023
-
FOI/2024/0179 - Water usage/ procurement
-
FOI/2024/0183 - Immunology Hidradenitis Suppurativa (HS) treatment